Modern options of prokinetics in gastroesophageal reflux disease treatment

Abstract

Aim of the lecture. To present modern approaches to prokinetic treatment at gastroesophageal reflux disease (GERD) to gastroenterologists. Summary. GERD belongs to acid-related diseases, because detrimental action of hydrochloric acid on esophageal mucosa plays major role in its pathogenesis. However esophageal and stomach motility disorders, e.g.: increase in frequency of transient lower esophageal sphincter relaxations, decrease of esophageal clearance and increase of intragastric pressure play important role in GERD development as well. These factors along with the not uncommon resistance of GERD patients to the proton pump inhibitors (PPI) caused by nonacidic refluxes require prokinetic administration. Most commonly prokinetics are prescribed as supplemental to PPI treatment. At the present time the optimal prokinetic drug, with proved efficacy at GERD and other diseases associated to gastrointestinal dysmotility is itopride hydrochloride (Ganaton®). Conclusion. Taken into account important role of esophageal and stomach dysmotility in GERD pathogenesis, prokinetics can be recommended for comprehensive disease treatment, especially at PPI inefficacy.

Keywords

• гастроэзофагеальная рефлюксная болезнь
• нарушения моторики пищевода и желудка
• прокинетики